Bringing a new neurological therapy, brain device or biomarker to market often requires years of development before commercial investors are willing to take the risk.

The National Institute of Neurological Disorders and Stroke Small Business Program provides non-dilutive SBIR and STTR funding to U.S. companies developing technologies aligned with the NINDS mission.

Current parent funding can reach $700,000 for Phase I and $3 million for Phase II.

What Does NINDS Fund?

NINDS supports commercial development of tools and technologies addressing neurological disorders and neuroscience research.

Areas of particular interest include:

• Novel technologies addressing unmet neurological needs;
• Therapeutics and biologics;
• Neurological diagnostics;
• Clinical and rehabilitation technologies;
• Brain-monitoring systems;
• In vivo testing;
• Biomarkers;
• Technologies requiring specialised facilities;
• Neuroscience research tools.

NINDS also supports relevant technologies connected with the BRAIN Initiative, including tools for understanding neural circuits and invasive or non-invasive devices for recording or modulating activity in the human central nervous system.

How Much Funding Is Available?

Current NINDS limits under both Parent SBIR and Parent STTR are:

Phase I: up to $700,000.

Phase II: up to $3 million.

NINDS also participates in the Phase IIB Strategic Breakthrough programme with a normal limit of $3 million.

Its current CRP limit is $2 million.

Clinical Trials

NINDS is comparatively flexible across NIH small-business mechanisms.

It accepts clinical trials through:

• SBIR;
• STTR;
• Phase IIB;
• CRP.

That does not mean every clinical trial is automatically appropriate.

Applicants should engage programme staff regarding trial design, development stage and institute fit.

Who Can Apply?

The applicant must be a qualifying U.S. small business concern.

For SBIR, the principal investigator is normally primarily employed by the business.

STTR allows the principal investigator to be employed by either the company or research institution, provided all STTR collaboration requirements are met.

Contact NINDS Before Applying

NINDS strongly encourages potential applicants to send staff a short abstract or overview of the technology at least one month before the standard SBIR/STTR deadline.

This is excellent advice.

The conversation can help determine whether the technology fits the institute, whether the proposed budget is realistic and whether another NIH mechanism may be more appropriate.

How to Improve Your NINDS Application

A strong neuroscience proposal should define the unmet need before describing the technology.

For a neurotechnology device, explain the current clinical workflow, shortcomings of existing devices and how your approach improves outcomes.

For a therapeutic, describe mechanism, supporting evidence and development milestones.

For a biomarker or diagnostic, explain how it changes clinical decision-making rather than only showing statistical performance.

Commercial potential also matters.

Who pays?

What regulatory pathway applies?

What evidence does the market require before adoption?

How large is the realistic patient or research market?

These questions should be addressed long before the final commercialisation plan is written.

Deadlines

The September 2026 cycle has passed.

The next standard deadline is January 5, 2027, followed by April 5.

Applicants should work backwards several months from the chosen deadline to allow time for programme discussions, registrations, research planning, budgets and internal review.

Explore official NINDS Small Business grants and guidance

For founders working at the intersection of neuroscience and commercial technology, NINDS offers an opportunity to finance difficult early development without giving away startup equity.